Stimulating Interactions


Blueprint Genetics Plans to Boost Inherited Disease Panel Portfolio Next Year

Finnish hereditary disease diagnostics firm Blueprint Genetics plans to significantly expand its portfolio of clinical gene panel tests next year, and in the meantime has been pushing into new territories, including the US. The Helsinki-based firm started offering diagnostic gene panels for inherited cardiovascular disorders two years ago, using a targeted sequencing technology called OS-Seq that one of its co-founders […]

Read more

Symic Biomedical Selects Osteoarthritis Clinical Candidate

Symic Biomedical, a clinical-stage biotherapeutics company developing multiple compounds that target and affect the extracellular matrix (ECM), today announced the selection of SB-061 as the company’s first osteoarthritis clinical candidate. In preclinical studies, SB-061 was shown to reduce pain and cartilage degradation in models of osteoarthritis. SB-061, which will be administered as an intra-articular injection, is designed to prevent the […]

Read more

A guy who hasn’t showered in 12 years just helped launch a skin care company

Forgoing a shower, even for a day, makes some people want to hide from society and double up on the deodorant. For Dave Whitlock, this is simply life as usual. The chemical engineer and MIT grad decided back in 2003 to stop showering after discovering that animals harness bacteria in mud to stay odor-free. Called Nitrosomonas, these bacteria break down […]

Read more

A new dawn for cataracts

On Thursday, November 6, scientists from ViewPoint Therapeutics published an article titled “Pharmacological chaperone for α-crystallin partially restores transparency in cataract models” in Science Magazine. The lead author: ViewPoint’s founder and CSO, Leah Makley. The summary below is from the linked perspective in the same issue. Cataract, a clouding of the eye lens, is the major cause of blindness in […]

Read more

Symic Biomedical Advances First Product Candidate, SB-030, Into Clinical Development

Symic Biomedical, a clinical-stage biotherapeutics platform company developing compounds that target the extracellular matrix (ECM), today announced the treatment of the first patient in its Phase 1/2 clinical Study in Humans to Investigate the Efficacy and Safety of Luminal SB-030 Delivery in Peripheral Artery Disease (SHIELD Trial). The study will evaluate the safety and efficacy of SB-030 (previously SBCV-030), a […]

Read more

Amarantus seeks US FDA orphan drug status for eltoprazine

Amarantus Bioscience Holdings, Inc., a biotechnology company, has submitted a request to the US FDA for orphan drug designation (ODD) for eltoprazine in the treatment of levodopa-induced dyskinesia (PD-LID). “A successful application to the US FDA for ODD for eltoprazine in PD LID would complete the transition of our therapeutics portfolio into the orphan drug arena, thereby squarely positioning Amarantus […]

Read more

Military researchers to conduct trial of Amarantus’s “engineered skin substitute”

Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds.  Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Array BioPharma, Inc. (NASDAQ: ARRY), Avanex Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO), and Progenix Pharmaceuticals, […]

Read more

Now You Can Buy Shampoo and Cleanser That Promote the Growth of “Good” Bacteria

If you’ve heard about probiotic cosmetic spray, it’s probably from a New York Times Magazine story published last year. In that article, journalist Julia Scott profiled the startup AOBiome and recounted her experience using the company’s signature product, a spray “contain[ing] billions of cultivated Nitrosomonas eutropha, an ammonia-oxidizing bacteria (AOB) that is most commonly found in dirt and untreated water.” […]

Read more

AOBiome Announces Start of First Clinical Trial with Ammonia Oxidizing Bacteria-Based Therapeutic for Treatment of Acne

AOBiome today announced it has begun a Phase 2 clinical trial with a therapeutic product candidate based on its proprietary ammonia oxidizing bacteria (AOB) for the treatment of mild to moderate acne vulgaris. The trial with the product candidate, B244, is being conducted under an IND application to the FDA and is the first to test the potential of live […]

Read more

Robots And Microbes: Zymergen Raises $44 Million From Big VCs

The two biology experts–one a biophysicist, one a biochemist–were studying microbes, the single-cell organisms found all over the planet, to see how they could be used as building blocks to produce new renewable materials. Sick of how slow the typical process can be, testing 10 ideas or so a month, they looked to robots to speed up their  painstaking lab […]

Read more
Page 5 of 8« First...34567...Last »

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals


953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287

Sign-Up for our Newsletter